Deal facts
- Buyer
- Merck KGaA, Darmstadt, Germany
- Target
- Rapid Micro Biosystems, Inc.
- Deal value
- Not disclosed
- Announced
- 16 November 2026
- Status
- Firm intention
- Sector
- Healthcare
- Country
- United States
- Consideration
- cash
Sources
Merck KGaA, Darmstadt, Germany has agreed to acquire Rapid Micro Biosystems, Inc. (Nasdaq: RPID) for cash. The Agreement and Plan of Merger was signed on November 16, 2026 with EMD Holdings NewCo II, Inc, a wholly owned Delaware subsidiary of Merck KGaA that will act as purchaser. Rapid Micro Biosystems disclosed the agreement the same day in a Form 8-K and said it issued a press release announcing it.
The purchaser will launch a cash tender offer for all Class A and Class B common stock at $0.75 per share, without interest and subject to tax withholding. The filing gives no aggregate deal value. The offer will initially expire one minute after 11:59 p.m. Eastern Time on the date 10 business days after it commences, and it can be extended in certain circumstances. As of the filing, the tender offer had not yet commenced.
The Company Board unanimously approved the agreement and recommended that stockholders tender their shares. Certain stockholders, including all board members and certain executive officers, who together beneficially own about 19.58% of the common stock signed Tender and Support Agreements committing them to tender. These agreements end on certain events, including a valid termination of the merger agreement. The Company agreed to no-shop restrictions with a fiduciary exception for unsolicited proposals that could lead to a superior proposal, and it owes Merck KGaA a $1,573,000 termination fee in specified circumstances, including a switch to a superior proposal or an adverse recommendation change.
Offer conditions include a majority minimum tender of Class A shares (counting Class A shares already held by Merck KGaA and its affiliates and including pre-funded warrant shares in the share count), accurate representations, covenant compliance, no continuing Material Adverse Effect, and no legal prohibition. After the offer is consummated, the purchaser will merge into the Company under Section 251(h) of the DGCL with no stockholder vote, leaving the Company as a wholly owned Merck KGaA subsidiary. Remaining shares convert into the $0.75 cash price, subject to appraisal rights. Vested options and RSUs are cashed out, unvested awards become cash-based awards on the original vesting schedule, and options with exercise prices at or above $0.75 are cancelled for no consideration. Warrants are treated by series: some are cashed out at the spread, the Series B warrants are purchased at Black Scholes value unless a holder elects otherwise under their terms, and the 2025 and 2018 warrants are cancelled without consideration.
Deal timeline
1 update- Firm intention
Merck KGaA, Darmstadt, Germany firm intention to acquire Rapid Micro Biosystems, Inc.
Item 1.01. Entry into a Material Definitive Agreement. On November 16, 2026, Rapid Micro Biosystems, Inc., a Delaware corporation (the “ Company ”), Merck KGaA, Darmstadt, Germany, a German corporation with general partners (“ Parent ”), and EMD Holdings NewCo II, Inc, a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”), entered into an Agreement and Plan of Merger (the
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Rosemont Pharmaceuticals Holdings, Inc. to acquire Aytu BioPharma Inc.
Aytu BioPharma Inc., a Nasdaq-listed Delaware company, agreed on November 16, 2026 to be acquired by Rosemont Pharmaceuticals Holdings, Inc. The two signed an Agreement…
- Buyer
- Rosemont Pharmaceuticals Holdings, Inc.
- Target
- Aytu BioPharma Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Merck KGaA, Darmstadt, Germany to acquire Silence Therapeutics plc
Merck KGaA, based in Darmstadt, Germany, has agreed to acquire Silence Therapeutics plc in a cash deal that will take the healthcare company private. The transaction, an…
- Buyer
- Merck KGaA, Darmstadt, Germany
- Target
- Silence Therapeutics plc
- Deal value
- Not disclosed
- Deal type
- going private
ArcheNova Technology Co., Ltd to acquire ArcheNova Biotech Corp.
ArcheNova Technology Co., Ltd has agreed to acquire ArcheNova Biotech Corp. in a transaction valued at two billion US dollars. The deal, announced on 13 October 2026, in…
- Buyer
- ArcheNova Technology Co., Ltd
- Target
- ArcheNova Biotech Corp.
- Deal value
- USD 2,000,000,000
- Deal type
- going private
Onyx Bidco LLC to acquire Option Care Health, Inc.
Option Care Health, Inc. entered into an Agreement and Plan of Merger on October 5, 2026 with Onyx Bidco LLC and its wholly owned subsidiary Onyx Merger Sub, Inc., both…
- Buyer
- Onyx Bidco LLC
- Target
- Option Care Health, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Lifecore Inc. to acquire Lifecore Biomedical, Inc.
Lifecore Inc. and Lifecore Biomedical, Inc. entered the Exit Mode archive.
- Buyer
- Lifecore Inc.
- Target
- Lifecore Biomedical, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Buyer history
Merck KGaA, Darmstadt, Germany
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive